Introduction
============

Purinergic signaling is emerging as one important mechanism of integrating functional activity between neurons, glial and vascular cells in the brain, through the action of both ATP and adenosine signaling ([@B5]). Adenosine is a cellular metabolite formed by the breakdown of adenine nucleotides and is physiologically present at nanomolar to micromolar concentrations inside and outside the cells ([@B23]). It represents an endogenous modulator of brain functions, fine-tuning glial function ([@B2]), blood flow ([@B35]), but also inhibitory and excitatory synaptic transmission ([@B52]); moreover, in the nervous system, the level of extracellular adenosine rises following brain damage, which occurs after stroke, ischemia, and epileptic seizures ([@B53]).

Basal extracellular adenosine concentration depends on the activity of both membrane nucleoside transporters ([@B47]; [@B16]), and extracellular ecto-nucleotidases ([@B68]). It has been reported that the synaptic concentration of adenosine, tightly controlled by astrocytes and neurons, is usually higher than the intracellular one, and tonically modulates synaptic activity acting on adenosine receptors (ARs) A~1~R and A~2A~R to regulate pre or post synaptic functions ([@B62]). The best characterized effect of adenosine is the presynaptic modulation of glutamatergic transmission ([@B19]): presynaptic activation of A~1~R reduces glutamate release ([@B63]), while activation of A~2A~R increases glutamatergic transmission ([@B59]; [@B9]; [@B39]).

It is also known that adenosine may modulate synaptic transmission also acting at the postsynaptic level ([@B29]; [@B62]), regulating the activity of neurotransmitter receptors. Specifically, A~1~R activation inhibits AMPA and NMDA induced currents in the hippocampus ([@B12]; [@B48]; [@B15]), while A~2A~R stimulation increases the amplitude of AMPA-evoked and miniature postsynaptic currents enhancing GluR1 phosphorylation at Ser845 ([@B15]). By contrast, few studies have focused on the role of A~3~ receptors (A~3~R) in synaptic modulation, although these receptors have been identified in neurons ([@B40]; [@B51]), astrocytes and microglial cells ([@B3]) and have a potential impact in glutamatergic modulation and synaptic plasticity ([@B8]; [@B43]; [@B48]), in addition to their involvement in pain modulation ([@B21]) and neuroprotection ([@B6]; [@B49]; [@B13]; [@B55], [@B56]).

In this study we demonstrate the ability of A~3~R to negatively modulate postsynaptic AMPA receptors through the reduction of GluR1 phosphorylation level. Moreover, this effect is synergistic with the A~1~R mediated reduction of AMPA currents, and counteracts the potentiating effect of A~2A~R activation. Importantly, we show that adenosine modulation is tonically active. Hence, the concomitant activity of A~1~R, A~2A~R, and A~3~R tightly tunes glutamatergic synapses, setting the properties of AMPA receptors functioning in basal conditions.

Materials and Methods {#s1}
=====================

Animals
-------

Procedures using laboratory animals were in accordance with the Italian and European guidelines and were approved by the Italian Ministry of Health in accordance with the guidelines on the ethical use of animals from the European Community Council Directive of 22 September 2010 (2010/63/EU). All efforts were made to minimize the number of animals used and their suffering.

Primary Hippocampal Neuronal Cultures
-------------------------------------

Hippocampal neuronal cultures were prepared as reported in [@B14], from newborn (P0-P1) C57BL/6 and KO mice of either sex (Charles River Laboratory). In brief, after careful dissection from diencephalic structures, the meninges were removed and the hippocampi were chopped and digested in 1.25 mg/ml trypsin for 20 min at 37°C. Cells were mechanically dissociated and plated at a density of 105 in poly-[L]{.smallcaps}-lysine coated glass coverslip (12 mm diameter) in serum-free Neurobasal medium, supplemented with B27 plus 2 mM [L]{.smallcaps}-glutamine and 100 μg/ml gentamicin (neuronal culture medium). Then, cells were kept at 37°C in 5% CO~2~ for 10--13 days with medium replacement (1:1 ratio) three times per week. With this method we obtained cultures composed by 60--70% neurons, 30--35% astrocytes, and 4--5% microglia, as determined with β-tubulin III, glial fibrillary acidic protein (GFAP), and isolectin IB4 staining ([@B37]). The same procedure was followed to prepare rat hippocampal culture used for some immunoblot experiments.

Glial Primary Cultures
----------------------

Primary cortical glial cells were prepared from P0--P2 mice. Cerebral cortices were chopped and digested in 30 U/ml papain for 40 min at 37°C and gently triturated. The dissociated cells were washed, suspended in Dulbecco's Modified Eagle Medium (DMEM, GIBCO) with Glutamax with 10% FBS (Invitrogen) and plated at a density of 9--10 × 105 in 175 cm^2^ cell culture flasks. At confluence (10--14 days *in vitro*, DIV), glial cells were shaken for 2 h at 37°C, to detach and remove microglial cells. These procedures gave almost pure astrocytes cell population (4--6% of microglia contamination), as verified by staining with GFAP and isolectin IB4 ([@B55]).

Slice Preparation
-----------------

Hippocampal slices were routinely prepared from 14- to 20-days old C57BL/6 mice (WT), A~1~R knockout mice (A~1~R KO; [@B32]), and the A~3~R knockout mice (A~3~R KO; [@B57]). The latter two groups of mice were backcrossed at least 10 times on a C57BL/6 background. Mice were decapitated under halothane anesthesia, and whole brains were rapidly removed and incubated in chilled artificial CSF (ACSF) for 15 min. Transverse hippocampal slices (250 μm) were cut at 4°C, using a Vibratome (DSK, Dosaka EM, Kyoto, Japan). Before use, slices were maintained for at least 1 h at room temperature (22--25°C) in oxygenated (95% O~2~, 5% CO~2~) ACSF, containing the following (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH~2~PO~4~, 26 NaHCO~3~, 2 CaCl~2~, 1 MgCl~2~, and 10 glucose, pH 7.35. All recordings were performed at room temperature on slices submerged in ACSF in the recording chamber. The ACSF was perfused at a rate of 1 ml/min.

Patch-clamp Recordings
----------------------

Patch-clamp recordings were obtained using glass electrodes (3--5 MΩ) filled with the following intracellular solution (in mM): 140 KCl, 2 MgCl~2~, 10 HEPES, 2 MgATP, 0.5 EGTA; pH 7.3, with KOH. During experiments, cultured neurons were continuously superfused with normal extracellular solution (NES) containing (in mM): 140 NaCl, 2.5 KCl, 2 CaCl~2~, 2 MgCl~2~, 10 HEPES-NaOH, and 10 glucose (pH 7.3), added with tetrodotoxin (0.2 μM), using a gravity driven perfusion system, consisting of independent tubes for standard and agonist-containing solutions, connected to a fast exchanger system used to delivery all agonists (RSC-100; Bio-Logic). To activate glutamate receptors in hippocampal neurons in acute slices, AMPA was delivered together with cyclothiazide (25 μM; Tocris Cookson) by pressure application (5--15 psi, 10--100 ms; Picospritzer II, General Valve, Fairfield, NJ, USA) from glass micropipettes positioned above the slice over the soma of the recorded neuron. All other agonists were applied to hippocampal slices by bath perfusion.

In all recordings, AMPA was delivered together with cyclothiazide, to avoid fast receptor desensitization ([@B27]) that could mask adenosine mediated AMPA receptor modulation. Cyclothiazide was always delivered in co-application with the agonist. Agonist concentration--current curves were constructed applying to each cell two or more different concentrations of agonist (10 nM--100 μM) at 60--120 s intervals and normalizing the current response to the plateau value, tested in all cells. Averaged data were best-fitted using Origin 7 (OriginLabCorp., Northampton, MA, USA) to the Hill equation:
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Where I~norm~ is the normalized current response, EC~50~ is the agonist concentration yielding half-maximal current response and nH is the Hill coefficient.

Membrane currents, recorded with a patch-clamp amplifier (Axopatch 200B; Molecular Devices, Foster city, CA, USA), were filtered at 2 kHz, digitized (10 kHz), and acquired with Clampex 10 software (Molecular Devices). The stability of the patch was checked by repetitively monitoring the input and series resistance during the experiment, and recordings were discarded when any of these parameters changed by \>10%.

All recordings were performed at 24--25°C, and cells were patch clamped at -70 mV.

Cell Stimulation and Western Blot Analysis
------------------------------------------

Ten DIV hippocampal cultures were incubated in Locke's buffer (in mM): 154 NaCl, 5.6 KCl, 3.6 NaHCO~3~, 2.3 CaCl~2~, 1 MgCl~2~, 5.6 glucose, buffered with 5 HEPES (pH 7.4) for 2 h and stimulated for 30 min with MRS1523 (100 nM).

Cells were then washed with PBS, scraped and lysed (Tris-HCl 50 mm pH 7.5, NaCl 150 mm, EGTA 1 mm, EDTA 1 mm, 1%, Triton X-100, 0.1% SDS, phosphatase and protease inhibitor mixture). Protein concentration was determined by BCA assay (Pierce), and the same amounts of proteins (30 μg) were separated on 10% SDS-PAGE and analyzed by Western immunoblot using with antibodies specific for phospho-GluR1 Ser845 (Upstate Biotechnology, Lake Placid, NY, USA), and actin (Sigma). Immunoreactivity was detected by chemiluminescence (Immun-Star WesternC Kit; Bio-Rad). Specific bands on chemiluminescence films were quantified by densitometry with Sigma Gel Software (Jandel Scientific, Erkrath, Germany).

Drugs
-----

SCH5821 (stock solution 10 mM in DMSO), DPCPX (stock solution 5 mM in DMSO), 2-Cl-IBMECA (stock solution 10 mM in DMSO), Bicuculline methochloride (stock solution 100 mM), AMPA (stock solution 100 mM), cyclothiazide (stock solution 50 mM in DMSO) and Tetrodotoxin citrate (stock solution 1 mM) were purchased from Tocris Bioscience, Bristol, UK. MRS1523 (stock solution 100 mM in DMSO) and all other drugs used were purchased from Sigma--Aldrich, Milan, Italy. Where not indicated, all drugs were dissolved in water.

Drug Application
----------------

During electrophysiological measurements, neurons were continuously superfused with NES, using a gravity driven perfusion system, consisting of independent tubes for standard and agonist-containing solutions, connected to a fast exchanger system (RSC-100; Bio-Logic) positioned 50--100 μm from the cell. Antagonists were usually acutely applied through parallel tubes of the same perfusion system or were pre-incubated for 1 h (37°C) and then continuously applied during the experiments.

Data Analysis
-------------

Data, analyzed oﬄine, are presented as mean ± SEM; we used the QuantityOne (Biorad) program for the densitometric analysis of all immunoblots. Origin 7 (Origin software; Microcal Software, Northampton, MA) and Sigmaplot 11 (Jandel scientific) software were used for statistical analysis. Paired and unpaired *t*-test and one-way ANOVA were used for parametrical data, as indicated; Holm--Sidak test was used as *post hoc* test; Mann and Withney test for non-parametrical data.

Results
=======

Modulation of AMPA Receptors by Basal Adenosine
-----------------------------------------------

It is well known that adenosine is present in brain extracellular space, as well as in neural preparations, such as brain slices or neuronal cultures. When we removed basal adenosine in hippocampal cultures with adenosine deaminase (ADA; 1 U/ml; 10 min), we observed a slow increase in the amplitude of currents evoked by AMPA application (10 μM; plus cyclothiazide, CTZ, 25 μM; to 120 ± 4%, *n* = 5, *p* \< 0.05; **Figure [1A](#F1){ref-type="fig"}**). This result suggests that adenosine present in the extracellular medium tonically depresses glutamatergic transmission by modulating the amplitude of AMPA currents.

![**Tonic activation of adenosine receptors modulates AMPA currents in mouse hippocampal neurons. (A)** time course and sample traces of AMPA current (AMPA 10 μM, CTZ 25 μM) potentiation induced by acute treatment with Adenosine deaminase (ADA, 1 U/ml, *n* = 5; *p* \< 0.05) in cultured hippocampal neurons. **(B)** Left, time course of AMPA current modulation by acute treatment with adenosine receptors antagonists blocking specifically: A~3~R (MRS1523, 100 nM, *n* = 5, purple), A~3~R + A~1~R (MRS1523 + DPCPX, *n* = 5, green) or A~2A~R (SCH58261 30 nM, *n* = 5, orange). Application of all drugs starts at *t* = 0, gray bar. Right, sample traces of AMPA currents in control (black) and in the presence of MRS1523 (purple) or SCH58261 (orange).](fncel-09-00409-g001){#F1}

To unveil the involvement of AR subtypes in AMPA current modulation, cultures were treated with specific ARs antagonists, in order to establish the possible contribution of A~1~R, A~2A~R, and A~3~R.

When control cultures were superfused with the A~3~R specific antagonist MRS1523 (100 nM, 8 min), we observed a significant increase in the amplitude of AMPA currents (to 123.1 ± 7.9%, *n* = 5; *p* \< 0.05; **Figure [1B](#F1){ref-type="fig"}**). A similar effect was obtained treating cultures with the A~1~R specific antagonist DPCPX (100 nM), causing current amplitude increase to 123.8 ± 13.5% (*n* = 10, *p* \< 0.05; not shown). Interestingly, when both A~3~R and A~1~R were blocked the current increase was significantly higher, suggesting an additive effect of the two antagonist (*n* = 5, *p* \< 0.05 vs. MRS1523 or DPCPX alone, one way ANOVA, Holm--Sidak, **Figure [1B](#F1){ref-type="fig"}**).

Conversely, the application of the specific A~2A~R antagonist SCH58261 (30 nM; 8 min) caused a decrease in current amplitude (to 80.8 ± 4.6%; *n* = 5, *p* \< 0.05; **Figure [1B](#F1){ref-type="fig"}**).

In addition, prolonged treatment of hippocampal cultures with specific ARs antagonists (30 min preincubation and during recordings) significantly affected the AMPA current response amplitude (10 μM plus CTZ, 25 μM; **Table [1](#T1){ref-type="table"}**); the mean current amplitude was in fact significantly enhanced by MRS1523 or DPCPX treatment, while it was reduced by SCH58261 (**Table [1](#T1){ref-type="table"}**).

###### 

Dose response parameters of AMPA response.

              Peak amplitude (pA) (*n*)   EC~50~ (μM) (*n*)     n~H~
  ----------- --------------------------- --------------------- -----------
  WT          678 ± 64 (53)               5.4 ± 0.7 (32)        1.6 ± 0.1
  MRS1523     1740 ± 520 (13)^∗∗^         1.3 ± 0.3 (11)^∗∗^    1.9 ± 0.3
  DPCPX       1420 ± 180 (12)^∗∗^         1.6 ± 0.2 (12)^∗^     2.1 ± 0.4
  SCH58261    504 ± 54 (9)^∗^             8.6 ± 0.5 (9)^∗∗^     1.4 ± 0.3
  A~3~R KO    1020 ± 93 (33)^∗∗^          1.2 ± 0.3 (11)^∗∗^    1.8 ± 0.2
  A~1~R KO    888 ± 130 (20)^∗^           1.9 ± 0.3 (8)^∗^      1.7 ± 0.3
  A~2A~R KO   754 ± 210 (13)              10.5 ± 0.6 (12)^∗∗^   1.5 ± 0.1

Data represent means ± SEM (number of cells) of: Column 2, mean Peak amplitude response to a test dose of agonist (AMPA 10 μM); Column 3, 4 fit parameters for dose-response curve fitted by Hill equation.

∗

p

\< 0.05 and

∗∗

p

\< 0.01, significantly different from control value in WT untreated neurons, as specified in Column 1.

These data indicate that in hippocampal cultures, ARs are tonically active due to the presence of adenosine in the extracellular medium, and that this has a modulatory effect on glutamatergic currents. The stimulation of A~3~R or A~1~R subtypes causes a tonic depression of AMPA receptors, while A~2A~R activation potentiates them; under basal condition, the inhibitory tone prevails, suggesting a predominance of A~1~R, A~3~R-mediated AMPAR modulation.

AMPA Receptors Affinity is Modulated by the Selective Activation of ARs
-----------------------------------------------------------------------

To understand how ARs activation could affect the AMPA receptor function, we measured the AMPA concentration--current response curve in hippocampal neurons, both in control conditions or interfering with basal ARs activation. In particular, to unveil the contribution of single AR subtypes to GluRs modulation, we selectively abolished specific ARs activity either pharmacologically or genetically, using hippocampal cultures derived from A~1~R, A~2A~R od A~3~R KO mice.

When WT cells were treated with MRS1523 (100 nM), to block A~3~R, we observed a leftward shift in the AMPA concentration--response curve (**Figure [2A](#F2){ref-type="fig"}**), corresponding to an increase in the agonist apparent affinity (**Figure [2A](#F2){ref-type="fig"}**; **Table [1](#T1){ref-type="table"}**, *n* = 11) with a EC~50~ value significantly different from the one observed in control conditions (**Table [1](#T1){ref-type="table"}**, *n* = 32, *p* \< 0.01), suggesting that basal A~3~R activation reduces GluR sensitivity for the agonist. Consistently, we observed an increase in the agonist affinity in hippocampal cultures derived from A~3~R KO mice (*n* = 11; **Figure [2A](#F2){ref-type="fig"}**; **Table [1](#T1){ref-type="table"}**, *p* \< 0.01).

![**Basal activation of AR subtypes changes the apparent affinity for AMPA. (A)** AMPA dose response curves (+ CTZ 25 μM) obtained in cultured hippocampal neurons in control (black, *n* = 32), in the presence of A~3~R antagonist MRS1523 (100 nM, *n* = 11, purple) and in neurons from A~3~R KO mice (*n* = 11, magenta). Inserts: sample traces representing current responses to 1, 10, and 100 μM AMPA (+ CTZ 25 μM) in WT and A~3~R KO hippocampal neurons. **(B)** AMPA dose response curves (+ CTZ 25 μM) obtained in cultured hippocampal neurons in the presence of A~2A~R antagonist SCH58261 (30 nM, *n* = 9, orange) and in neurons from A~2A~R KO mice (*n* = 12; red; control condition in black). Inserts: representative current responses to 1, 10, and 100 μM AMPA (+ CTZ 25 μM) in A~2A~R KO hippocampal neurons.](fncel-09-00409-g002){#F2}

Analogously, both the pharmacological inhibition by DPCPX (10 nM; *n* = 12) and the genetic deletion of A~1~R (hippocampal cultures derived from A~1~R KO mice), caused an increase in AMPA potency (**Table [1](#T1){ref-type="table"}**, *n* = 8; *p* \< 0.05).

Conversely, when A~2A~R was inhibited by SCH58261 or deleted in A~2A~R KO cultures, the apparent affinity for AMPA was decreased (*n* = 9, *p* \< 0.05 and *n* = 12, *p* \< 0.01 respectively; **Figure [2B](#F2){ref-type="fig"}**; **Table [1](#T1){ref-type="table"}**).

Altogether, these data indicate that GluRs functional properties are finely tuned by activation of different AR subtypes by basal adenosine. The sensitivity of GluRs is modulated in opposite directions by activation of ARs and in particular, A~3~R or A~1~R decrease agonist affinity, while it is increased by A~2A~R.

Neuronal A~3~R Regulates AMPA Receptors Function Through Modulation of GluR1-Ser845 Phosphorylation
---------------------------------------------------------------------------------------------------

To investigate the cellular and molecular determinants underlying the A~3~R mediated modulation of AMPA currents, we performed experiments using the specific A~3~R agonist 2-Cl-IBMECA. To remove basal activation of ARs, control hippocampal cultures were treated with ADA (1 U/ml, 1 h pre-application and during the experiment) and current amplitude was monitored during the application of the specific A~3~R agonist 2-Cl-IBMECA. Consistently with the above reported results with A~3~R antagonist, the application of 2-Cl-IBMECA (10 nM, 10 min) reduced the AMPA current amplitude (to 60 ± 11%, *n* = 12, *p* \< 0.01; **Figure [3A](#F3){ref-type="fig"}**).

![**AMPARs function modulation requires neuronal A~3~R activation. (A)** Reduction of AMPA current amplitude induced by the application of A~3~R agonist 2-Cl-IBMECA in cultured hippocampal neurons treated with Adenosine deaminase (1 U/ml, 1 h preincubation + perfusion); bar chart representing the effect observed in WT cultures (black; *n* = 12); or A~3~R KO cultures (magenta; *n* = 13); gray column represents the effect of 2-Cl-IBMECA in A~3~R KO cultures in the presence of WT glial cells (*n* = 12). **(B)** Sample traces showing the effect of 2-Cl-IBMECA on AMPA currents in hippocampal neurons from WT (top) and A~3~R KO (bottom) mice, co-cultured with WT glial cells. ^∗∗^*p* \< 0.01.](fncel-09-00409-g003){#F3}

As expected, in cultures prepared from A~3~R KO mice, 2-Cl-IBMECA failed to reduce AMPA current (103 ± 3%; *n* = 13; *p* = 0.67; **Figure [3A](#F3){ref-type="fig"}**), confirming that the observed effect was ascribable to specific A~3~R stimulation. To evaluate the possible contribution of glial A~3~R in the AMPA current modulation, we explored if glial A~3~R stimulation could rescue AMPA current modulation. To this purpose, A~3~R KO hippocampal cultures were seeded on a feeding layer of either A~3~R KO or WT glial cells: 2-Cl-IBMECA was ineffective both in A~3~R KO cultures seeded on WT glia (*n* = 14, *p* = 0.84; **Figures [3A,B](#F3){ref-type="fig"}**) and co-cultured with A~3~R KO glia (*n* = 12, *p* = 0.91), strongly indicating that 2-Cl-IBMECA acts specifically on neuronal A~3~R to modulate AMPA function.

Since A~3~R stimulation reduces cAMP accumulation ([@B67]), and PKA is responsible for GluR1 phosphorylation at Ser845 ([@B1]), we studied the contribution of A~3~R in AMPAR phosphorylation to understand the intracellular pathway leading to the AMPA current modulation. To address this issue, ATP was substituted in the intracellular solution by ATPγS, in order to promote irreversible substrate thio-phosphorylation ([@B20]) and thus to prevent the AMPAR dephosphorylation. As reported in **Figure [4A](#F4){ref-type="fig"}**, in this experimental condition 2-Cl-IBMECA (10 nM, ADA 1U/ml, *n* = 6, *p* \< 0.05) failed to reduce the AMPA current amplitude. Consistently, MRS1523 (100 nM) application failed to potentiate AMPA-mediated currents when neuronal PKA was inhibited by intracellular perfusion with KT5720 (**Figure [4B](#F4){ref-type="fig"}**; *n* = 6; *p* = 0.83).

![**A~3~R dependent AMPARs modulation requires GluR1 dephosphorylation. (A)** Time course of the effect of the A~3~R agonist 2-Cl-IBMECA on AMPA current amplitude in the continuous presence of ADA (1 U/ml, 1 h preincubation) in control condition (black, *n* = 12) and after substitution of intracellular ATP with the thiophosphorylating agent ATPγS (*n* = 6). **(B)** Bar chart and sample traces displaying mean AMPA current potentiation induced by A~3~R antagonist MRS1523 in control and in the presence of PKA blocker KT5720 (*n* = 6). **(C)** Representative immunoblot and quantitative western blot analysis of the effect of MRS1523 on the level of basal Glur1 Ser845 phosphorylation (*n* = 13). ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01.](fncel-09-00409-g004){#F4}

To test whether A~3~R modulation of AMPA currents could be associated to changes in GluR1 phosphorylation level, we exposed hippocampal cultures to MRS1523 (100 nM, 30 min) and evaluated the level of GluR1 phosphorylation at Ser845. Quantitative western blot analysis showed that, in MRS1523 treated cultures, the Ser845 phosphorylation increased to 125.6 ± 11.8% (*n* = 13, *p* \< 0.03; **Figure [4C](#F4){ref-type="fig"}**), indicating that tonic A~3~R activity reduces GluR1 phosphorylation. Altogether, these results indicate that the A~3~R activation modulates GluR functions through receptor dephosphorylation.

Modulation of Postsynaptic AMPA Receptors in Acute Hippocampal Slices by A~1~R, A~2A~R and A~3~R Activation
-----------------------------------------------------------------------------------------------------------

To disclose the postsynaptic modulation of glutamatergic currents by ARs activation in hippocampal slices, we recorded the effect of the high affinity AR agonist *N*-ethyl 1-5′ carboxamido adenosine (NECA) application on currents evoked by repetitive pressure application of AMPA (100 μM, plus CTZ 25μM) on CA1 pyramidal neurons. Prolonged NECA application (100 nM; 25 min) caused a reduction in the AMPA current amplitude (to 86.9 ± 2.2%, *p* \< 0.01 paired *t*-test; *n* = 6; **Figure [5A](#F5){ref-type="fig"}**), which did not recover within 20 min after drug washout (**Figure [5A](#F5){ref-type="fig"}**). We used combinations of specific ARs antagonist to disclose the contribution of single receptor subtypes (**Figure [5B](#F5){ref-type="fig"}**). In the presence of DPCPX (100 nM) plus SCH58261 (30 nM), allowing only the activation of A~3~R, NECA caused a reduction of the AMPA current amplitude (to 78.6 ± 4.5%; *n* = 5; *p* \< 0.01, paired *t*-test), followed by a slow recovery after drug withdrawal. Smaller depression (to 90.0 ± 3.6%; *n* = 6, *p* \< 0.05, paired *t*-test) was observed when NECA was applied in the presence of SCH58261 plus MRS1523 (100 nM), allowing only the activation of A~1~R (*p* \< 0.05 respect to NECA in the presence of DPCPX plus SCH58261; One way ANOVA, Holm--Sidak, **Figure [5C](#F5){ref-type="fig"}**). Conversely, in the presence of DPCPX plus MRS1523, NECA caused AMPA current potentiation, due to A~2A~R stimulation (to 108.5 ± 5.1%, *n* = 6, *p* \< 0.05, paired *t*-test). All together, these results indicate that also in hippocampal slices, activation of A~1~R, A~2A~R and A~3~R modulates AMPA receptors.

![***N*-ethyl 1-5′ carboxamido adenosine (NECA) modulates postsynaptic AMPA receptors through multiple ARs. (A)** Time course and representative traces of AMPA (100 μM plus CTZ 25 μM) current amplitude reduction induced by NECA (*t* = 25 min) (100 nM) in hippocampal CA1 neurons (*n* = 6; *p* \< 0.01). **(B,C)** Time course and bar chart (at *t* = 25 min) of the effect of NECA in the presence of combination of ARs antagonists: DPCPX (100 nM) plus MRS1523 (100 nM) (gray; *n* = 6; *p* \< 0.01); SCH58261 (30 nM) plus MRS1523 (dark green; *n* = 6; *p* \< 0.05); DPCPX plus SCH58261 (green; *n* = 5; *p* \< 0.01). ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01.](fncel-09-00409-g005){#F5}

To verify whether ARs modulation of AMPA receptors might affect glutamatergic synaptic transmission, we recorded, in CA1 pyramidal neurons, the excitatory postsynaptic currents (EPSCs) evoked by Schaffer collaterals stimulation. In this condition, we observed that basal adenosine, present in the slice preparation, modulates glutamatergic synaptic currents being EPSC amplitude increased by acute ADA application (Supplementary Figure [S1A](#SM1){ref-type="supplementary-material"}). Moreover, as revealed using A~1~RKO and A~3~RKO mice, the application of high dose of adenosine induced an EPSC depression depending on both A~1~R and A~3~R (Supplementary Figures [S1B,C](#SM1){ref-type="supplementary-material"}). In addition, NECA application caused a reduction of EPSCs amplitude (*n* = 7; *p* \< 0.05; **Figure [6A](#F6){ref-type="fig"}**), without affecting the paired pulse ratio (not shown), supporting a postsynaptic action of NECA that largely depends on the A~3~R activation. Indeed, NECA-mediated EPSCs depression was significantly smaller when A~3~R was blocked (MRS1523 100 nM, *n* = 4, *p* \< 0.05 respect to NECA alone, one way ANOVA, Holm--Sidak; **Figure [6B](#F6){ref-type="fig"}**), and it was abolished when A~1~R and A~2A~R blockers (DPCPX 100 nM, SCH58261 30 nM) were simultaneously added (*n* = 7, *p* \< 0.01 respect to NECA alone, one way ANOVA, Holm--Sidak; **Figure [6B](#F6){ref-type="fig"}**).

![**Modulation of EPSC amplitude by NECA depends on A~3~R. (A)** *Left*, time course of EPSC depression induced by adenosine receptor agonist NECA (100 nM) in hippocampal CA1 neurons in from acute slices in control conditions *(black; n* = 7; *p* \< 0.05 at *t* = 25 min), in the presence of A~3~R antagonist MRS1523 (100 nM) (purple; *n* = 7; *p* \< 0.05 respect to control and NECA alone) and in the presence of DPCPX + SCH58261 + MRS1523 (gray, *n* = 7). *Right*, sample EPCSs recorded in a CA1 pyramidal neuron in control and following NECA application. **(B)** Bar chart showing the effect of NECA (100 nM) alone (black), in the presence of the A~3~R antagonist (MRS1523 100 nM, purple) and in the presence of all three blockers (DPCPX + SCH58261+MRS1523 gray, *n* = 7). ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^\#^*p* \< 0.05.](fncel-09-00409-g006){#F6}

These data confirm that the A~3~R activation may modulate glutamatergic synaptic transmission by a postsynaptic mechanism affecting AMPA receptor functions.

Discussion
==========

We report here that adenosine present in the extracellular milieu may tonically regulate the function of AMPA receptors acting on A~1~R, A~2A~R, and A~3~R. Our data show that adenosine exerts multiple effects on glutamatergic transmission, modulating in opposite direction the apparent affinity of AMPA receptors, depending on AR subtypes. Our study is particularly focused on the effects of A~3~R stimulation, highlighting the role of this AR subtype in the modulation of glutamatergic transmission.

We propose that the A~3~R modulation of AMPA receptors is based on the alteration of the phosphorylation balance, at GluR1-Ser845, leading to changes in the apparent agonist affinity of the receptor. It is well known that phosphorylation affects the properties of the glutamate receptors ([@B1]) shifting the sensitivity to the transmitter/agonist ([@B38]); similar mechanisms could be involved in adenosine-based forms of synaptic modulation and plasticity ([@B50]; [@B37]; [@B48]; [@B58]). Our data show that the A~3~R stimulation causes a depression of the AMPA currents, which is likely associated with receptor dephosphorylation, since it is absent in the presence of ATPγS which promotes irreversible thio-phosphorylation of substrates ([@B20]). Consistently, the treatment with the specific A~3~R blocker MRS1523 (i) causes the increase in the AMPA current amplitude, as confirmed in experiments on A~3~R KO cultures; (ii) is associated to the increase in the level of GluR1-Ser845 phosphorylation and (iii) is blocked by the PKA antagonist KT5720. Indeed, adenosine is known to act through intracellular pathways involving PKA ([@B24]), potentially interfering with the phosphorylation of GluRs. In line with this, it has been shown that A~2A~Rs stimulation leads to the potentiation of glutamatergic currents in hippocampal neurons and to GluR1 phosphorylation ([@B15]). It has to be considered that both A~1~R and A~3~R are coupled to Gi/Go proteins, and that their activation leads to a decrease in the level of cAMP ([@B46]; [@B41]). It can be thus hypothesized that the concomitant block of A~1~R and A~3~R will consistently increase the level of cAMP, possibly leading to a bigger effect respect to the one observed with a single receptor antagonist.

The effect of ARs stimulation on the amplitude of AMPA-evoked currents is observed both in hippocampal cultures and in acute slices. It can be speculated that the modulation of agonist affinity may have relevance only on extrasynaptic GluRs, physiologically activated by low concentration of glutamate, as it is has been shown for adenosine modulation of GABA receptors ([@B54]). Indeed, our results show that the ARs stimulation by NECA, in particular A~3~R activation, also affects glutamatergic synaptic transmission in hippocampal slices, where GluRs are activated by high transmitter concentration ([@B7]), depressing EPSCs amplitude. Moreover, EPSCs depression is not associated to a change in the paired pulse ratio, indicating a postsynaptic mechanism ([@B18]).

It should be noted that EPSCs depression induced by NECA shows a peculiar pharmacology, likely reflecting a preferential action of the agonist on postsynaptic A~3~R, due to the higher NECA affinity for A~3~R compared to other ARs ([@B44]; [@B45]; [@B10]). Indeed, in our experimental conditions, extracellular adenosine might activate or desensitize presynaptic A~1~R. Thus, in addition to the well known A~1~R presynaptic modulation ([@B63]; [@B60], [@B61]; [@B2]), the ARs stimulation may depress EPSCs by an A~3~R-dependent postsynaptic mechanism. The involvement of A~3~R in the glutamatergic synaptic modulation has been previously reported ([@B4]; [@B8]; [@B48]), particularly in hypoxic conditions ([@B31]; [@B49]), when the adenosine extracellular level is highly increased ([@B23]).

While interpreting the pharmacological results, it should be considered that basal adenosine may affect ARs to different extent; due to their desensitization properties ([@B33]) and that phenomena of re-sensitization may occur ([@B34]). In this respect, we consider convincing the consistency of data obtained with pharmacological and knock out approaches.

Results from this study clearly point to a role of basal adenosine in glutamatergic modulation; our data from hippocampal cultures show that removing different ARs, either by pharmacological or genetic approaches, causes changes in the functional properties of AMPA receptors (current amplitude and affinity for the agonist), pointing to tonic receptor modulation by ambient adenosine. Indeed, the AMPA current reduction induced by 2-Cl-IB-MECA was more pronounced in the presence of ADA (see [@B48]), suggesting that basal adenosine might occlude the effect of exogenous agonist application.

It could be speculated that ADA might modulate *per se* AMPA receptor activity, however, although it has been hypothesized the ability of ADA to act independently from its enzymatic activity ([@B22]; [@B66]), no data have been reported concerning the effect of extracellular ADA on the modulation of neurotransmitter receptors.

It should be noted that purines are released by brain cells through different mechanisms ([@B36]) and that adenosine concentration may rise to the nanomolar range in hippocampal slices ([@B11]). It can be speculated that this situation does not reflect the physiological status, representing one of the effects connected to slice or culture unnatural conditions ([@B69]). On the other hand, high adenosine level may be present in restricted sites during high level of activity or in pathological conditions ([@B53]; [@B64]).

Our results show that adenosine may influence the glutamatergic neurotransmission through several independent mechanisms; in particular we show that the modulation of AMPA receptor by A~1~R ([@B37]) is synergic with that of A~3~R, counteracting A~2A~R-dependent AMPA receptor potentiation (see also [@B15]). A~1~R, A~2A~R and A~3~R are widely expressed at hippocampal synapses, both pre- and post-synaptically ([@B40]; [@B51]). ARs are also expressed on glial cells ([@B5]), however, in our conditions, the exclusive expression of A~3~R on glial cells was not sufficient to rescue the AMPA receptor modulation in A~3~R KO cultures, highlighting the role of neuronal A~3~R in A~3~R-dependent modulation.

It should be emphasized that the relevance and even the sign of adenosine modulation of synaptic transmission and plasticity ([@B58]) will strongly depend on the level of expression and the regional distribution of different AR subtypes ([@B17]; [@B26]; [@B28]; [@B30]). We speculate that this pathway of synaptic modulation could be suitable for the independent tuning of single synapses ([@B65]). In addition, it has been proposed that due to time and space constraints, the source of adenosine may determine the AR subtype to be activated: adenosine originating from ATP released by astrocytes seems to target excitatory A~2A~R ([@B9]), while released adenosine seems to prefer A~1~R ([@B42]).

Since A~3~R is known to have lower affinity for adenosine ([@B45], but see [@B25]) compared to A~1~R and A~2A~R, its activity may be relevant especially after acute brain insults, such as in ischemia and traumatic brain injury, when the extracellular level of adenosine dramatically increases ([@B23]). In particular, the A~3~R activation can contribute to reduce over-excitability in order to counteract brain damage.

Conclusion
==========

We show that adenosine, an ubiquitous brain mediator, may tune synaptic transmission through multiple mechanisms depending on the AR subtype expression. Such mechanisms of regulation are potentially highly relevant in the fine regulation of single synapses in relation to the level of synaptic activity or other conditions leading to the local increase of adenosine concentration.
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